Patents by Inventor Philip Leighton

Philip Leighton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11542319
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: January 3, 2023
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Publication number: 20220256820
    Abstract: This disclosure provides, among other things, strategies for minimizing antibody diversification in a transgenic animal that uses gene conversion for antibody diversification. In some embodiments, the animal may comprise a genome comprising an endogenous immunoglobulin light chain locus comprising: (a) a functional immunoglobulin light chain gene comprising a nucleic acid encoding a light chain variable region; and (b) a plurality of pseudogenes that are operably linked to the functional immunoglobulin light chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding a light chain variable region, wherein the pseudogenes are upstream or downstream of the functional immunoglobulin light chain gene and encode the same amino acid sequence as the light chain variable region of the functional immunoglobulin light chain gene of (a). In other embodiments, the locus may have a tandem array of coding sequences for the light chain.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 18, 2022
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 11337409
    Abstract: This disclosure provides, among other things, strategies for minimizing antibody diversification in a transgenic animal that uses gene conversion for antibody diversification. In some embodiments, the animal may comprise a genome comprising an endogenous immunoglobulin light chain locus comprising: (a) a functional immunoglobulin light chain gene comprising a nucleic acid encoding a light chain variable region; and (b) a plurality of pseudogenes that are operably linked to the functional immunoglobulin light chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding a light chain variable region, wherein the pseudogenes are upstream or downstream of the functional immunoglobulin light chain gene and encode the same amino acid sequence as the light chain variable region of the functional immunoglobulin light chain gene of (a). In other embodiments, the locus may have a tandem array of coding sequences for the light chain.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: May 24, 2022
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 11179506
    Abstract: An apparatus is including a negative pressure wound therapy pump including a pump housing; and a negative pressure wound therapy canister attached to and readily removable from the pump housing; the canister including a flexible conduit; the canister operable to receive suction generated by the pump; the flexible conduit sized, shaped, and located to interface with the pump housing of the pump such that suction produced by the pump is transmitted to the canister via the flexible conduit.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: November 23, 2021
    Assignee: Cork Medical, LLC
    Inventors: Aaron Barr, John Anthony Lamper, Philip Leighton Ramge, Elliott Conrad Lasher
  • Publication number: 20210230629
    Abstract: This disclosure provides, among other things, a transgenic animal that uses gene conversion for antibody diversification comprising B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a human heavy chain variable domain; and (b) a plurality of pseudogenes that are operably linked to the functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the human heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene and encode variable domains that have camelizing amino acid substitutions.
    Type: Application
    Filed: June 5, 2019
    Publication date: July 29, 2021
    Inventors: William Don HARRIMAN, Philip A. LEIGHTON
  • Publication number: 20210230253
    Abstract: This disclosure provides, among other things, a transgenic chicken. In some embodiments, the transgenic chicken comprises B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a heavy chain variable domain in which the CDR3 is in the range of 30-60 amino acids in length and comprises at least 2 cysteine residues; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.
    Type: Application
    Filed: June 5, 2019
    Publication date: July 29, 2021
    Inventors: William Don HARRIMAN, Philip A. LEIGHTON
  • Publication number: 20210227810
    Abstract: This disclosure provides, among other things, a transgenic animal that uses gene conversion for antibody diversification, comprising B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding an autonomous heavy chain (AHC) variable domain; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the AHC variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.
    Type: Application
    Filed: June 5, 2019
    Publication date: July 29, 2021
    Inventors: William Don HARRIMAN, Philip A. LEIGHTON
  • Publication number: 20210227811
    Abstract: Provided herein is a transgenic chicken comprising a genome having an endogenous immunoglobulin heavy chain gene in which the IgY CH1 coding sequence is functionally deleted. In certain embodiments, in B cells of the chicken the endogenous immunoglobulin heavy chain gene comprises: (a) a functional immunoglobulin heavy chain gene comprising, in operable linkage, a nucleic acid encoding an antibody heavy chain variable domain and a constant region coding sequence in which the IgY CH1 coding sequence is functionally deleted; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the variable domain of (a), wherein the pseudogenes are upstream of the nucleic acid encoding an antibody heavy chain variable domain of (a).
    Type: Application
    Filed: June 5, 2019
    Publication date: July 29, 2021
    Inventors: Philip A. LEIGHTON, William Don HARRIMAN
  • Patent number: 11033009
    Abstract: This disclosure provides, among other things, a transgenic animal and a method of using the same to make antibodies that have a common light chain. In certain embodiments, the transgenic animal may comprising a genome comprising a common light chain transgene, wherein the common light chain transgene comprises a non-immunoglobulin light-chain promoter and a common light-chain coding sequence. In certain embodiments, the common light chain is constitutively expressed.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 15, 2021
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Publication number: 20210169055
    Abstract: This disclosure provides, among other things, strategies for minimizing antibody diversification in a transgenic animal that uses gene conversion for antibody diversification. In some embodiments, the animal may comprise a genome comprising an endogenous immunoglobulin light chain locus comprising: (a) a functional immunoglobulin light chain gene comprising a nucleic acid encoding a light chain variable region; and (b) a plurality of pseudogenes that are operably linked to the functional immunoglobulin light chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding a light chain variable region, wherein the pseudogenes are upstream or downstream of the functional immunoglobulin light chain gene and encode the same amino acid sequence as the light chain variable region of the functional immunoglobulin light chain gene of (a). In other embodiments, the locus may have a tandem array of coding sequences for the light chain.
    Type: Application
    Filed: June 5, 2019
    Publication date: June 10, 2021
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Publication number: 20210163983
    Abstract: This disclosure provides, among other things, strategies for minimizing antibody diversification in a transgenic animal that uses gene conversion for antibody diversification. In some embodiments, the animal may comprise a genome comprising an endogenous immunoglobulin light chain locus comprising: (a) a functional immunoglobulin light chain gene comprising a nucleic acid encoding a light chain variable region; and (b) a plurality of pseudogenes that are operably linked to the functional immunoglobulin light chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding a light chain variable region, wherein the pseudogenes are upstream or downstream of the functional immunoglobulin light chain gene and encode the same amino acid sequence as the light chain variable region of the functional immunoglobulin light chain gene of (a). In other embodiments, the locus may have a tandem array of coding sequences for the light chain.
    Type: Application
    Filed: June 5, 2019
    Publication date: June 3, 2021
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Publication number: 20210000088
    Abstract: A transgenic chicken having a genome comprising a modified immunoglobulin heavy chain (IgH) locus is provided. The locus lacks the entire contiguous endogenous chicken V-D-J region and contains a human VH segment, a human D cluster, a human J segment and a plurality of upstream pseudogenes based on human VH sequences. The modified IgH locus undergoes V(D)J recombination in the chicken and the chicken produces antibodies that have a diversified immunoglobulin heavy chain.
    Type: Application
    Filed: March 5, 2019
    Publication date: January 7, 2021
    Inventors: Philip A. Leighton, William Don Harriman
  • Publication number: 20200308255
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Application
    Filed: May 15, 2020
    Publication date: October 1, 2020
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 10687519
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: June 23, 2020
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10689433
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: June 23, 2020
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Publication number: 20190320630
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Application
    Filed: May 31, 2019
    Publication date: October 24, 2019
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10362770
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: July 30, 2019
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Publication number: 20190141967
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Application
    Filed: December 4, 2018
    Publication date: May 16, 2019
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10172334
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 8, 2019
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Publication number: 20180338479
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Application
    Filed: June 1, 2018
    Publication date: November 29, 2018
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton